Title:
BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/148422
Kind Code:
A1
Abstract:
Provided herein are Bridged Compounds having the following structures: (I) wherein R 1a, R 1b, R 1c, R 1d, R 2a, R 2b, R 2c, R 2d, R 3a, R 3b, R 3c, R 3d, R 4, R 5, R 6, R 7, R 8, m1, m2, m3, n2, n3, n4, q, X 1, X 2, Y 1, Y 2, L 1 and ring A are as defined herein, compositions comprising an effective amount of a Bridged Compound, and methods for treating or preventing various diseases, e.g., pancreatic cancer, or a condition treatable or preventable by inhibition of the function of KRAS protein. In another aspect, a Bridged Compound is useful for treating or preventing a condition treatable or preventable by inhibition of the function of KRAS protein with G12D mutation. In another aspect, a Bridged Compound is useful for treating or preventing a condition treatable or preventable by inhibition of a RAS/MAPK pathway.
Inventors:
JI QI (CN)
YU CHAO (CN)
WANG CE (CN)
SUN HANZI (CN)
YUAN HAO (CN)
WANG ZHIWEI (CN)
YU CHAO (CN)
WANG CE (CN)
SUN HANZI (CN)
YUAN HAO (CN)
WANG ZHIWEI (CN)
Application Number:
PCT/CN2022/070676
Publication Date:
July 14, 2022
Filing Date:
January 07, 2022
Export Citation:
Assignee:
BEIGENE LTD (GB)
JI QI (CN)
JI QI (CN)
International Classes:
C07D487/08; A61K31/517; A61P35/00; C07D498/08
Domestic Patent References:
WO2021107160A1 | 2021-06-03 | |||
WO2021106231A1 | 2021-06-03 | |||
WO2021031952A1 | 2021-02-25 | |||
WO2017172979A1 | 2017-10-05 | |||
WO2020216190A1 | 2020-10-29 |
Foreign References:
CN110869358A | 2020-03-06 |
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF:
Previous Patent: BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF
Next Patent: MOVING OBJECT DETECTION METHOD AND APPARATUS
Next Patent: MOVING OBJECT DETECTION METHOD AND APPARATUS